Lovenox Quest For Fresh Patent Continues; ANDAs May Face “Premarin” Problem
Executive Summary
Aventis will continue to pursue a re-issuance of its low weight heparinLovenox patent despite a second rejection by the Patent & Trademark Office
You may also be interested in...
Sandoz Omnitrope NDA Is Test For Follow-On Biologics; Pfizer Says No
Sandoz' pending NDA for Omnitrope appears ripe for an FDA decision
Lovenox Patent Re-Issuance Denied: Aventis To Submit Response Shortly
Aventis plans to submit additional information on Lovenox to the Patent & Trademark Office after the agency denied re-issuance of a patent central to the company's defense against enoxaparin generics
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011